Table 1. The prevalence of prolonged neuromuscular symptoms among COVID-19 survivors.

Symptoms	Year	Study design	City	Country	Day from discharge to follow-up Day (±SD) or Day (min-max)	Prevalence of prolonged neuromuscular symptoms over total followed COVID-19 survivors			NOS	Reference
						No patients	Total patients	Percentage
Fatigue	2020	Prospective	Wuhan	China	14	7	131	5.3	7	[55]
	2020	Prospective	Isfahan	Iran	72 (62–87)	50	452	11.1	9	[54]
	2021	Cohort	Hubei	China	153 (146–160)	1038	1655	62.7	8	[50]
	2020	prospective	Fuyang	China	90	4	60	6.7	7	[52]
	2020	Cohort	Georgia	USA	38 (21–49)	17	26	65.4	8	[48]
	2021	Prospective	Wuhan	China	97 (95–102)	152	538	28.3	8	[58]
	2020	Prospective	Aachen	Germany	56 (48–71)	15	33	45.5	8	[49]
	2020	Prospective	Henan	China	90	9	55	16.4	7	[57]
	2020	Prospective	Wuhan	China	14	5	337	1.5	7	[56]
	2020	Prospective	Dublin	Ireland		22	128	17.2	9	[33]
	2020	Prospective	Rome	Italy	60.3 (±13.6)	76	143	53.1	7	[47]
	2020	Prospective	Tokyo	Japan	108 (±23)	10	58	17.2	7	[53]
	2020	Prospective	Wuhan	China	28	1	38	2.6	7	[59]
	2020	Prospective	Wuhan	China	90	45	76	59.2	8	[51]
	Total					1451	3730	38.9
Anosmia	2020	Prospective	Isfahan	Iran	28	21	452	4.6	9	[54]
	2021	Cohort	Hubei	China	153 (146–160)	176	1655	10.6	8	[50]
	2020	Prospective	Fuyang	China	90	2	60	3.3	7	[52]
	2020	Cohort	Georgia	USA	38 (21–49)	8	26	30.8	8	[48]
	2020	Prospective	Aachen	Germany	56 (48–71)	4	33	12.1	8	[49]
	2020	Prospective	California	USA	9.4 (3.8–14.8)	18	316	5.7	8	[60]
	2020	Prospective	Tokyo	Japan	108 (±23)	10	58	17.2	7	[53]
	Total					239	2600	9.2
Headache	2020	Prospective	Isfahan	Iran	28	12	452	2.7	9	[54]
	2020	Prospective	Wuhan	China	14	5	131	3.8	7	[55]
	2021	Cohort	Hubei	China	153 (146–160)	33	1655	2.0	8	[50]
	2020	Prospective	Fuyang	China	90	6	60	10.0	7	[52]
	2020	Cohort	Georgia	USA	38 (21–49)	13	26	50.0	8	[48]
	2020	Prospective	Aachen	Germany	56 (48–71)	5	33	15.2	8	[49]
	2020	Prospective	Henan	China	90	10	55	18.2	7	[57]
	Total					84	2412	3.5
Myalgia	2021	Cohort	Hubei	China	153 (146–160)	39	1655	2.4	8	[50]
	2020	Prospective	Wuhan	China	14	1	131	0.8	7	[55]
	2020	Prospective	Fuyang	China	90	15	60	25.0	7	[52]
	2020	Cohort	Georgia	USA	38 (21–49)	7	26	26.9	8	[48]
	2021	Prospective	Wuhan	China	97 (95–102)	24	538	4.5	8	[58]
	2020	Prospective	Aachen	Germany	56 (48–71)	5	33	15.2	8	[49]
	2020	Prospective	Wuhan	China	14	1	337	0.3	7	[56]
	Total					53	1125	4.7
Joint pain	2021	Cohort	Hubei	China	153 (146–160)	154	1655	9.3	8	[50]
	2020	Cohort	Georgia	USA	38 (21–49)	8	26	30.8	8	[48]
	2021	Prospective	Wuhan	China	97 (95–102)	41	538	7.6	8	[58]
	2020	Prospective	Rome	Italy	60.3 (±13.6)	39	143	27.3	7	[47]
	Total					242	2362	10.2

Min-max: minimum-maximum, NOS: Newcastle-Ottawa scale, SD: standard deviation